← FDA DRUG APPROVALS

FDA ANDA · ANDA078957

STAVUDINE

Sponsor: HETERO LABS LTD III

APPLICATION
ANDA078957
TYPE
ANDA
ORIGINAL APPROVAL
2008-12-29
LATEST ACTION
2015-06-24
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

STAVUDINEDiscontinued
STAVUDINE 20MG · CAPSULE · ORAL
STAVUDINEDiscontinued
STAVUDINE 30MG · CAPSULE · ORAL
STAVUDINEDiscontinued
STAVUDINE 15MG · CAPSULE · ORAL
STAVUDINEDiscontinued
STAVUDINE 40MG · CAPSULE · ORAL

Approval history

2015-06-24Manufacturing (CMC) · Supplement 5 · unknownAP
2009-09-02Labeling · Supplement 2AP
2009-05-27Labeling · Supplement 1AP
2008-12-29OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →